RB1 and p53 at the crossroad of EMT and triple-negative breast cancer

Jiang, Zhe; Jones, Robert A.; Liu, Jeff C.; Deng, Tao; Robinson, Tyler; Chung, Philip E.D.; Wang, Sharon; Herschkowitz, Jason I.; Egan, Sean E.; Perou, Charles M.; Zacksenhaus, Eldad

doi:10.4161/cc.10.10.15703

Cited by 97 publications

(82 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study is not the first observation of the involvement of EMT in TNBC (28,29). However, unlike previous studies, our observation is that TNBC that express IL32 also appear to be enriched in genes involved in EMT.…”

Section: Continued Analysis Of the Differentially Expressed Gene: Expcontrasting

confidence: 56%

Identification of Genes Differentially Associated with Triple Negative Breast Cancers

Abraham¹,

Kwende²,

Player³

2017

ARC Journal of Cancer Science

View full text Add to dashboard Cite

Section: Continued Analysis Of the Differentially Expressed Gene: Expcontrasting

confidence: 56%

Identification of Genes Differentially Associated with Triple Negative Breast Cancers

Abraham¹,

Kwende²,

Player³

2017

ARC Journal of Cancer Science

View full text Add to dashboard Cite

“…CNAs, including CCND1 gene amplification, Rb1 deletion, and CHEK2 deletion, were correlated with poor survival in the young breast cancer group, suggesting that the aberrations of these genes can be used as prognosis markers for young breast cancer. RB1 is frequently lost in TNBC 21 and is involved in epithelial-mesenchymal transition. 22 This also provides insights into the poor survival of the young breast cancer group.…”

Section: Discussionmentioning

confidence: 99%

Multi-gene fluorescence in situ hybridization to detect cell cycle gene copy number aberrations in young breast cancer patients

Bai

Xia

et al. 2014

Cell Cycle

View full text Add to dashboard Cite

“…71 Reduced E-cadherin expression may also have a role in the poor prognosis in TNBCs. 72 A semiquantitative H-score is a method for scoring biomarkers with nuclear staining, such as ER and PR.…”

mentioning

confidence: 99%

Update on Immunohistochemical Analysis in Breast Lesions

Peng¹,

Butt²,

Chen³

et al. 2017

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.-The utility of immunohistochemistry (IHC) in breast lesions needs to be updated with exceptions among these lesions. Biomarker studies with IHC in triple-negative breast carcinoma may help develop targeted therapies for this aggressive breast cancer. The distinction of metastatic lung adenocarcinoma to the breast and invasive breast carcinoma has significant prognostic and therapeutic implications. The determination can be challenging because both primary tumors can express estrogen receptor and/or HER2 by IHC, creating a diagnostic dilemma.Objectives.-To provide a practical update on the use of IHC markers in differential diagnoses in breast lesions, including benign, atypical, precancerous, and malignant tumors; to highlight recently published research findings on novel IHC markers in triple-negative breast carcinoma cases; and to reinforce the importance of IHC use as an ancillary tool in distinguishing metastatic lung adenocarcinoma to the breast from primary breast carcinoma using real case examples.Data Sources.-PubMed (US National Library of Medicine, Bethesda, Maryland) literature review and authors' research data and personal experiences were used in this review.Conclusions.-Immunohistochemistry has an important role in making differential diagnoses in breast lesions in morphologically equivocal settings; recognizing IHC expression status in the exceptions among these lesions will aid in the correct diagnosis of challenging breast cases. Studies suggest that androgen receptor, p16, p53, GATA3, and PELP1 may have potential diagnostic, prognostic, and predictive value in triple-negative breast carcinoma cases; these findings may provide insight and a greater understanding of the tumor biology in triple-negative breast carcinomas. In distinguishing metastatic estrogen receptor-positive or HER2 þ lung adenocarcinoma to the breast from primary breast carcinoma, napsin A, TTF-1, and GATA3 comprise a useful IHC panel.

show abstract

RB1 and p53 at the crossroad of EMT and triple-negative breast cancer

Cited by 97 publications

References 104 publications

Identification of Genes Differentially Associated with Triple Negative Breast Cancers

Identification of Genes Differentially Associated with Triple Negative Breast Cancers

Multi-gene fluorescence in situ hybridization to detect cell cycle gene copy number aberrations in young breast cancer patients

Update on Immunohistochemical Analysis in Breast Lesions

Contact Info

Product

Resources

About